Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Women's Health
Published in: BMC Women's Health 1/2021

Open Access 01-12-2021 | Breast Cancer | Research article

Understanding low chemoprevention uptake by women at high risk of breast cancer: findings from a qualitative inductive study of women’s risk-reduction experiences

Authors: Tasleem J. Padamsee, Megan Hils, Anna Muraveva

Published in: BMC Women's Health | Issue 1/2021

Login to get access

Abstract

Background

Chemoprevention is one of several methods that have been developed to help high-risk women reduce their risk of breast cancer. Reasons for the low uptake of chemoprevention are poorly understood. This paper seeks a deeper understanding of this phenomenon by drawing on women’s own narratives about their awareness of chemoprevention and their risk-related experiences.

Methods

This research is based on a parent project that included fifty in-depth, semi-structured interviews with a purposive sample of African American and White women at elevated risk of breast cancer. This specific study draws on the forty-seven interviews conducted with women at high or severe risk of breast cancer, all of whom are eligible to use chemoprevention for breast cancer risk-reduction. Interviews were analyzed using grounded theory methods.

Results

Forty-five percent of participants, and only 21% of African American participants, were aware of chemoprevention options. Women who had seen specialists were more likely to be aware, particularly if they had ongoing specialist access. Aware and unaware women relied on different types of sources for prevention-related information. Those whose main source of information was a healthcare provider were more likely to know about chemoprevention. Aware women used more nuanced information gathering strategies and worried more about cancer. Women simultaneously considered all risk-reduction options they knew about. Those who knew about chemoprevention but were reluctant to use it felt this way for multiple reasons, having to do with potential side effects, perceived extreme-ness of the intervention, similarity to chemotherapy, unknown information about chemoprevention, and reluctance to take medications in general.

Conclusions

Lack of chemoprevention awareness is a critical gap in women’s ability to make health-protective choices. Future research in this field must consider complexities in both women’s perspectives on chemoprevention and the reasons they are reluctant to use it.
Appendix
Available only for authorised users
Literature
1.
Holmberg C. Decision making in the context of breast cancer chemoprevention: patient perceptions and the meaning of risk. Am Soc Clin Oncol Educ Book ASCO Am Soc Clin Oncol Meet. 2015;35:e59-64.
2.
3.
Padamsee TJ, Muraveva A, Yee LD, et al. Experiencing the cancer of a loved one influences decision-making for breast cancer prevention. J Health Psychol. 2017; 1359105317746480.
4.
Chlebowski RT. IBIS-I Tamoxifen update: maturity brings questions. The Lancet. 2015;16:7–8.PubMed
5.
Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16:67–75.PubMedPubMedCentral
6.
Freedman A, Yu B, Gail M, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol. 2011;29:2327–33.PubMedPubMedCentral
7.
Vogel VG, Constantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila Pa). 2010;3:696–706.
8.
9.
Martinez KA, Fagerlin A, Witteman HO, et al. What matters to women when making decisions about breast cancer chemoprevention? The Patient. 2016;9:149–59.PubMedPubMedCentral
10.
Pujol P, Lasset C, Berthet P, et al. Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: The LIBER trial. Fam Cancer. 2012;11:77–84.PubMed
11.
Smith SG, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2016;27:575–90.
12.
Waters EA, Cronin KA, Graubard BI, et al. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Prev Biomark. 2010;19:443–6.
13.
Blakeslee SB, McCaskill-Stevens W, Parker PA, et al. Deciding on breast cancer risk reduction: the role of counseling in individual decision-making—a qualitative study. Patient Educ Couns. 2017;100:2346–54.PubMedPubMedCentral
14.
Liede A, Mansfield CA, Metcalfe KA, et al. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Res Treat. 2017;165:433–44.PubMedPubMedCentral
15.
Meiser B, Wong WKT, Peate M, et al. Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review. Hered Cancer Clin Pract. 2017;15:14–14.PubMedPubMedCentral
16.
Razzaboni E, Toss A, Cortesi L, et al. Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy). Breast J. 2013;19:10–21.PubMed
17.
Metcalfe KA, Kim-Sing C, Ghadirian P, et al. Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation. Clin Genet. 2014;85(1):21–30. PubMed
18.
Reimers LL, Sivasubramanian PS, Hershman D, et al. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. Breast J. 2015;21:377–86.PubMedPubMedCentral
19.
Trivedi MS, Coe AM, Vanegas A, et al. Chemoprevention uptake among women with atypical hyperplasia and lobular and ductal carcinoma in situ. Cancer Prev Res (Phila Pa). 2017;10:434.
20.
Bambhroliya A, Chavez-MacGregor M, Brewster AM. Barriers to the use of breast cancer risk reduction therapies. J Natl Compr Cancer Netw J Natl Compr Canc Netw. 2015;13:927–35.
21.
Crew KD, Albain KS, Hershman DL, et al. How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer. 2017;3:20.PubMedPubMedCentral
22.
Noonan S, Pasa A, Fontana V, et al. A survey among breast cancer specialists on the low uptake of therapeutic prevention with tamoxifen or raloxifene. Cancer Prev Res (Phila Pa). 2018;11:38.
23.
Smith SG, Foy R, McGowan JA, et al. Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs’ attitudes. Br J Gen Pract. 2017;67:e414.PubMedPubMedCentral
24.
Dillard AJ, Scherer L, Ubel PA, et al. Breast cancer anxiety’s associations with responses to a chemoprevention decision aid. Soc Sci Med. 1982;2013(77):13–9.
25.
Flanagan MR, Zabor EC, Stempel M, et al. Chemoprevention uptake for breast cancer risk reduction varies by risk factor. Ann Surg Oncol. 2019;26:2127–35.PubMedPubMedCentral
26.
Gunn CM, Bokhour BG, Parker VA, et al. Understanding decision making about breast cancer prevention in action: the intersection of perceived risk, perceived control, and social context: NRG Oncology/NSABP DMP-1. Med Decis Making. 2019;39:217–27.PubMedPubMedCentral
27.
28.
Holmberg C, Daly M, McCaskill-Stevens W. SI RLTD: risk scores and decision making: the anatomy of a decision to reduce breast cancer risk. J Nurs Healthc Chronic Illn. 2010;2:271–80.PubMedPubMedCentral
29.
Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3090–5.
30.
Crew KD. Addressing barriers to uptake of breast cancer chemoprevention for patients and providers. Am Soc Clin Oncol Educ Book ASCO Am Soc Clin Oncol Meet. 2015;35:e50-58.
31.
Nichols HB, DeRoo LA, Scharf DR, et al. Risk-benefit profiles of women using tamoxifen for chemoprevention. J Natl Cancer Inst. 2015;107:354.PubMed
32.
Roche CA, Tang R, Coopey SB, et al. Chemoprevention acceptance and adherence in women with high-risk breast lesions. Breast J. 2019;25:190–5.PubMed
33.
Thorneloe RJ, Horne R, Side L, et al. Beliefs about medication and uptake of preventive therapy in women at increased risk of breast cancer: results from a multicenter prospective study. Clin Breast Cancer. 2019;19:e116–26.PubMedPubMedCentral
34.
Korfage IJ, Fuhrel-Forbis A, Ubel PA, et al. Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. Breast Cancer Res. 2013;15:R74.PubMedPubMedCentral
35.
Kukafka R, Fang J, Vanegas A, et al. Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting. BMC Med Inform Decis Mak. 2018;18:134–134.PubMedPubMedCentral
36.
Rondanina G, Puntoni M, Severi G, et al. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:1537–43.
37.
DeCensi A, Thorat MA, Bonanni B, et al. Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. Ecancermedicalscience. 2015;9:595.PubMedPubMedCentral
38.
Cyrus-David MS. The future of women of minority race/ethnicity in breast cancer chemoprevention therapy. Ethn Dis. 2006;16:216–22.PubMed
39.
Holmberg C, Whitehouse K, Daly M, et al. Gaining control over breast cancer risk: Transforming vulnerability, uncertainty, and the future through clinical trial participation—a qualitative study. Sociol Health Illn. 2015;37:1373–87.PubMedPubMedCentral
40.
Padamsee TJ, Hils M, Muraveva A. Supplementary File—Interview protocol. 2021. Supplementary file associated with this manuscript.
41.
Hampel H, Sweet K, Westman JA, et al. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet. 2004;41:81–91.PubMedPubMedCentral
42.
Charmaz K. Constructing grounded theory. 2nd ed. Los Angeles: Sage Publications; 2014.
43.
44.
Meadows RJ, Padamsee TJ, Paskett ED. Distinctive psychological and social experiences of women choosing prophylactic oophorectomy for cancer prevention. Health Care Women Int. 2018;39(5):595–616.PubMedPubMedCentral
45.
Padamsee TJ, Muraveva A, Meadows RJ, Hils M, Yee LD, Wills CE, Paskett ED. Racial differences in prevention decision making among women at high risk of breast cancer: a qualitative study. Under Rev. 2021.
46.
Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. New York: Aldine de Gruyter; 1967.
47.
Patton MQ. Qualitative research and evaluation methods. 4th ed. Los Angeles: Sage Publications; 2015.
48.
Padamsee T, Paskett ED. Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res. 2017;34:1–12.
49.
Bober SL, Hoke LA, Duda RB, et al. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:4951–7.
50.
Hum S, Wu M, Pruthi S, et al. Physician and patient barriers to breast cancer preventive therapy. Curr Breast Cancer Rep. 2016;8:158–64.PubMedPubMedCentral
51.
Ralph AF, Ager B, Bell ML, et al. Women’s preferences for selective estrogen reuptake modulators: an investigation using protection motivation theory. Patient Educ Couns. 2014;96:106–12.PubMed
52.
Collins IM, Steel E, Mann GB, et al. Assessing and managing breast cancer risk: clinicians’ current practice and future needs. Breast. 2014;23(5):644–50.PubMed
53.
Corbelli J, Borrero S, Bonnema R, et al. Use of the Gail model and breast cancer preventive therapy among three primary care specialties. J Womens Health. 2014;23(9):746–52.
54.
Hum S, Wu M, Pruthi S, et al. Physician and patient barriers to breast cancer preventive therapy. Curr Breast Cancer Rep. 2016;8(3):158–64.PubMedPubMedCentral
55.
Bidassie B, Kovach A, Vallette MA, et al. Breast cancer risk assessment and chemoprevention use among veterans affairs primary care providers: a national online Survey. Mil Med. 2020;185(3–4):512–8.PubMed
56.
Lee SI, Curtis H, Qureshi S, et al. Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer: a cross-sectional survey in England. J Community Genet. 2021;12(1):111–20.PubMed
57.
Smith SG, Side L, Meisel SF, et al. Clinician-reported barriers to implementing breast cancer chemoprevention in the UK: a qualitative investigation. Public Health Genomics. 2016;19(4):239–49.PubMed
58.
Heisey R, Pimlott N, Clemons M, et al. Women’s views on chemoprevention of breast cancer: qualitative study. Can Fam Physician Med Fam Can. 2006;52:624–5.
59.
Donnelly LS, Evans DG, Wiseman J, et al. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer. 2014;110:1681–7.PubMedPubMedCentral
Metadata
Title
Understanding low chemoprevention uptake by women at high risk of breast cancer: findings from a qualitative inductive study of women’s risk-reduction experiences
Authors
Tasleem J. Padamsee
Megan Hils
Anna Muraveva
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2021
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-021-01279-4

Other articles of this Issue 1/2021

BMC Women's Health 1/2021 Go to the issue

Research

Ten-year follow up of cosmetic outcome, overall survival, and disease-free survival in endoscope-assisted partial mastectomy with filling of dead space using absorbable mesh for stage ≤ IIA breast cancer: comparison with conventional conservative method

Research article

Ex-vivo forces associated with intrauterine device placement and perforation: a biomechanical evaluation of hysterectomy specimens

Research

Significance of the viral load of high-risk HPV in the diagnosis and prediction of cervical lesions: a retrospective study

Research

The effect of a training program on maternal role adaptation and self-esteem of mothers with preterm infants: a quasi-experimental study

Research

Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity

Research article

Analysis of basal serum TSH, FT3, and FT4 levels based on age, sampling time in women with infertility